Table 3. Univariate and multivariate analysis of progression-free survival in patients with metastatic nasopharyngeal carcinoma patients (unmatched data).
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | ||
| Sex | 0.286 | ||||
| Female vs. male | 0.81 (0.54–1.20) | ||||
| Age, years | 0.112 | ||||
| >50 vs. ≤50 | 1.26 (0.95–1.67) | ||||
| T classification | |||||
| T1 | 1 | ||||
| T2 | 1.00 (0.58–1.71) | 0.994 | |||
| T3 | 1.33 (0.81–2.18) | 0.261 | |||
| T4 | 1.20 (0.73–2.00) | 0.472 | |||
| N classification | |||||
| N0 | 1 | ||||
| N1 | 1.21 (0.16–9.01) | 0.852 | |||
| N2 | 1.58 (0.22–11.39) | 0.649 | |||
| N3 | 2.47 (0.34–17.72) | 0.369 | |||
| Histology | |||||
| I | 1 | ||||
| II | 0.55 (0.29–1.05) | 0.07 | |||
| III | 0.79 (0.255–2.48) | 0.69 | |||
| ECOG | 0.38 | ||||
| 1 vs. 0 | 1.19 (0.80–1.77) | ||||
| IMRT | 0.004 | 0.034 | |||
| Yes vs. no | 0.66 (0.49–0.88) | 0.73 (0.54–0.98) | |||
| SII | <0.001 | 0.002 | |||
| ≥930 vs. <930 | 1.84 (1.34–2.54) | 1.69 (1.22–2.35) | |||
ECOG, Eastern Cooperative Oncology Group performance; IMRT, intensity modulated radiotherapy; HR, hazard ratio; CI, confidence interval. SII, systemic immune-inflammation index.